



Introduction to the Anthrax Vaccine Work Group

Brendan Jackson, MD, MPH

Captain, U.S. Public Health Service

Principal Deputy Director

Division of High-Consequence Pathogens and Pathology

June 26, 2025

Advisory Committee on Immunization Practices

Public Health Problem

- *Bacillus anthracis*, the causative agent of anthrax, is an endospore-forming bacterium found naturally in soil around the world
- Humans are most often infected by exposure to infected animals or animal by-products via cutaneous, gastrointestinal, or inhalational routes
- *Bacillus anthracis* is a Tier 1 select agent
 - Potential for use as a bioweapon
 - High case fatality rate
 - Ability to cause great harm to public health and safety, particularly when aerosolized

Anthrax Vaccine Work Group

- **Vaccine:** Anthrax vaccine adsorbed, adjuvanted (AVA,A) (Cyfendus)
 - Second-generation anthrax vaccine
 - Licensed in July of 2023 for post-exposure prophylaxis (PEP) following exposure to *Bacillus anthracis* in adults aged 18 to 65
- **Work Group Objective:** Review existing safety and immunogenicity data to develop recommendations for ACIP to consider for domestic use of AVA,A for anthrax PEP

Thank you.

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

